| Literature DB >> 30828720 |
Lucia Haronikova1, Vanesa Olivares-Illana2, Lixiao Wang3, Konstantinos Karakostis4, Sa Chen3, Robin Fåhraeus1,3,4,5.
Abstract
A large number of signalling pathways converge on p53 to induce different cellular stress responses that aim to promote cell cycle arrest and repair or, if the damage is too severe, to induce irreversible senescence or apoptosis. The differentiation of p53 activity towards specific cellular outcomes is tightly regulated via a hierarchical order of post-translational modifications and regulated protein-protein interactions. The mechanisms governing these processes provide a model for how cells optimize the genetic information for maximal diversity. The p53 mRNA also plays a role in this process and this review aims to illustrate how protein and RNA interactions throughout the p53 mRNA in response to different signalling pathways control RNA stability, translation efficiency or alternative initiation of translation. We also describe how a p53 mRNA platform shows riboswitch-like features and controls the rate of p53 synthesis, protein stability and modifications of the nascent p53 protein. A single cancer-derived synonymous mutation disrupts the folding of this platform and prevents p53 activation following DNA damage. The role of the p53 mRNA as a target for signalling pathways illustrates how mRNA sequences have co-evolved with the function of the encoded protein and sheds new light on the information hidden within mRNAs.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30828720 PMCID: PMC6468297 DOI: 10.1093/nar/gkz124
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1.Cell stress-dependent regulation of alternative initiation of p53 mRNA translation. Alternative translation initiation of the p53 mRNA generates two isoforms, p53 full length (p53FL) and p53/p47. The activation of the ATM kinase (Ataxia Telangiectasia Mutated) following DNA damage results in the induction of p53FL synthesis from +1 AUG. The full-length p53 includes the TA I (transactivation domain I) that is required for induction of p53 target genes, including the G1 cell cycle kinase inhibitor p21CDKN1A or pro-apoptotic factors such as Bax, Puma or Noxa of the Bcl-2 family, to mention just a few. The activation of the Unfolded Protein Response (UPR) pathway following stress to the endoplasmic reticulum activates the PERK kinase and the initiation of the p53/47 isoform at the second in frame AUG at +120. P53/47 lacks TA I but retains TA II and causes G2/M arrest via induction of 14-3-3σ, or a BIK-dependent apoptosis by suppressing the BiP chaperone. Apart from the box I, the p53 mRNA harbours four other conserved domains (II to V) within the DNA binding domain (164). Different p53 protein functional domains are indicated: trans-activation domains I & II (TA I & II); poly-proline rich region (PPP); oligomerization domain (OD); regulatory domain (RD). For a more comprehensive overview of signalling pathways activating p53 please see (3,4).
p53 mRNA 3′UTR binding factors
| Binding factor | Name | Binding sequence/region | Assay | Consequences | References |
|---|---|---|---|---|---|
|
| Human antigen R | AU-rich element/U-rich element | RNA EMSA, supershift, RNA-protein pulldown, IP of RNP complexes and RT-PCR, colocalization of HuR and p53 mRNA on cells polysomes, siRNA of HuR and impact on RNA stability, luciferase assay | HuR stabilizes | Mazan-Mamczarz 2003; Galbán 2003; Zou 2006; Tong 2009 |
|
| Hematopoietic zinc finger protein | AU-rich element/U-rich element | RNA EMSA, supershift, luciferase assay, IP of RNP complexes and PCR | p19Arf signalling leads to HuR and Hzf mediated | Nakamura 2011 |
|
| Long non-coding RNA 7SL | AU-rich element/U-rich element | RNA-protein pulldown, luciferase assay, colocalization on polysomes | lnc RNA 7SL represses | Abdelmohsen 2014 |
|
| - | AU-rich element/U-rich element | luciferase assay, RNA-Protein crosslink, colocalization on polysomes | miRNA 125b supresses translation following genotoxic stress. Interaction competed by HuR | Ahuja 2016 |
|
| Wild-type p53-induced gene 1 | AU-rich element | luciferase assay, IP of RNP complexes and RT-PCR, RNA-protein pulldown | Wig-1 binds to and stabilizes | Vilborg 2009 |
|
| Poly(A)-specific ribonuclease | AU-rich element | RNA EMSA, supershift, RNA-protein pulldown, luciferase assay, IP of RNP complexes and RT-PCR, | PARN deadenylase destabilizing | Devany 2013 |
|
| Cytoplasmic polyadenylation element-binding protein 1 | cytoplasmic polyA signal | IP of RNP complexes and RT-PCR | CPEB1 knockdown resulted in decreased | Burns 2008; Burns 2011; Glahder 2011 |
|
| RNA binding motif protein 38 | U -rich element | RNA EMSA, IP of RNP complexes and RT-PCR | RBM38 binds to 5′ and 3′ UTR and inhibits translation. RBM38 upon phosphorylation at Ser 195 turns from being repressor to activator of p53 translation. RBM38 is dephosphorylated by PPM1D phosphatase resulting in p53 translational repression | Zhang 2011; Zhang 2013; Zhang 2015 |
|
| RNA binding motif protein 24 | U -rich element | RNA EMSA, IP of RNP complexes and RT-PCR, luciferase assay | RBM24 repress p53 translation by prevnting the interaction with eIF4E. | Zhang 2018 |
|
| Cytotoxic granule associated RNA binding protein | U -rich element | iCLIP, luciferase assay | Tia1 targets | Díaz-Muñoz 2017 |
|
| - | U-rich element | Luciferase assay, RNA-Protein crosslink | - | Fu 1999 |
*For review of miRNA see Liu et al. 2017.
Figure 2.p53 mRNA interacting factors. In response to particular cellular conditions, a multitude of different proteins and RNA molecules interact with the p53 mRNA to control p53 expression. The cartoon shows some p53 mRNA binding factors. Please see also Tables 1, 3 and 4.
p53 mRNA 5′UTR binding factors
| Binding factor | Name | Binding sequence/region | Assay | Consequences | References |
|---|---|---|---|---|---|
|
| Cellular tumor antigen p53 | –216 to +1 | RNA-protein pull down | p53 binds to the 5′ UTR region and inhibits its own mRNA translation. | Mosner 1995 |
|
| Ribosomal protein L26 | –191 to 2 | RNA EMSA; IP-RT-PCR | RPL26 preferentially binds to the 5′ UTR after DNA damage and enhances translation. | Takagi 2005 |
|
| Nucleolin | –191 to 2 | RNA EMSA; IP-RT-PCR | Nucleolin overexpression suppresses p53 translation | Takagi 2005 |
|
| WD repeat containing antisense to TP53 | IRES I | Luciferase assays; RNase protection assay; RNA-ChIP | Overexpression of Wrap53 increases | Mahmoudi 2009 |
|
| RNA binding motif protein 38 | IRES I | RNA EMSA; RT-PCR; Quantitative PCR; RNA-ChIP | RNPC1 inhibits expression of p53 via | Zhang 2011 |
|
| Programmed cell death 4 | IRES I | IP-RT–PCR | The translation inhibitory effect of Pdcd4 is mediated by the 5′UTR and depends on the ability to interact with eIF4A. | Wedeken 2011 |
|
| Heterogeneous nuclear ribonucleoprotein Q | IRES I | UV cross-linking followed by Immunoprecipitation (CLIP) | hnRNP Q binds to the 5′UTR of mouse | Kim 2013 |
|
| Polypyrimidine tract-binding protein | IRES I | UV cross-linking followed by Immunoprecipitation (CLIP) | PTB is an IRES trans-acting factor that positively regulates p53 IRES-I activity. | Khan 2013 |
|
| Death associate protein 5 (also NAT1 or p97) | IRES I | RNA-protein crosslink; Bicistronic constructs; Luciferase assay; IP of RNP complexes and RT-PCR | Positively regulate the translation of various IRES containing mRNAs, promotes IRES-driven translation including the | Weingasten-Gabbay 2014 |
|
| Translational control protein 80 | IRES I | Dual-Luciferase assays; IP-RT-PCR | Overexpression of TCP80, together with RHA, leads to enhanced p53 expression. | Halaby 2015 |
|
| RNA helicase A | IRES I | Dual-Luciferase Assays; IP-RT-PCR | Enhances | Halaby 2015 |
|
| Ku | IRES I | IP-RT-PCR ; RNA EMSA; UV cross-linking | Ku represses p53 protein synthesis and p53-mediated apoptosis by binding to a bulged stem-loop structure within the 5′ UTR. | Lamaa 2016 |
|
| Heterogeneous nuclear ribonucleoprotein L | IRES I | IP-RT-PCR | hnRNP L binds the 5′UTR. Knockout of hnRNP L decrease of p53 levels | Seo 2017 |
**PTB also interacts with the 3′UTR (Katoch et al. 2017).
p53 mRNA coding region binding factors
| Binding factor | Name | Binding sequence/region | Assay | Physiological consequences/cellular conditions | References |
|---|---|---|---|---|---|
|
| Death associate protein 5 (also NAT1 or p97) | IRES I and II | RNA-protein crosslink; Bicistronic constructs; Luciferase assay; IP of RNP complexes and RT-PCR | Enhances p53/47 expression and to a lesser extend p53 full length. | Weingasten-Gabbay 2014 |
|
| Polypyrimidine-tract-binding protein | –1 to +39 (IRES II) | Bicistronic constructs; Luciferase assay; Filter binding assay | Enhances p53 and p53/47 translation following genotoxic stress. | Grover 2008 |
|
| PTB associated Splicing Factor | +1 to +251 | RNA affinity chromatography (RNA-protein pull-down), IP of RNP complexes and RT-PCR; Filter binding assay | Enhance p53 and p53/47 expression. | Sharathchandra 2012 |
|
| Annexin A2 | +1 to +251 | RNA affinity chromatography (RNA-protein pull-down), IP of RNP complexes and RT-PCR; Filter binding assay | Enhances p53 and p53/47 translation in a Ca2+ dependent fashion after thapsigargin- induced ER stress. | Sharathchandra 2012 |
|
| Murine double minute 4 | IRES II | RNA-IP: RNA ELISA | Chaperoning | Malbert-Colas 2014 |
|
| Murine double minute 2 | IRES II | RNA-IP; RNA EMSA; RNA-ELISA | Enhance p53 translation during genotoxic stress. | Candeias 2008, Gajjar 2012 |
|
| Amyloid precursor protein | +1 to +120 | RNA-IP; RNA-protein pull down; Luciferase assay; Bicistronic constructs | Enhances p53/47 expression. | Li 2015 |
|
| Thymidylate synthase | +531 to +1020 | IP of RNP complexes and RT-PCR; In vitro translation assay; RNA EMSA | Represses translation. The levels of | Chu 1999 |
Diseases associated synonymous mutation on p53
| Region | Disease | Interacting factor | Type | Physiological consequences/cellular conditions | References |
|---|---|---|---|---|---|
|
| Colorectal carcinomas | MDM2 | Mutation | V10V (GTC>GTT) silent mutation with reduces affinity for MDM2, then with lower p53 expression levels. | Hayes 1999; Candeias |
|
| Chronic lymphocytic leukemia | MDM2 | Mutation | L22L (CUA> CUG) silent mutation impair Mdm2-mediated enhancement of | Oscier 2002 |
|
| Nonmelanoma skin cancer | MDM2 | Mutation | P36P (CCG>CCT) silent mutations has a reduce affinity for MDM2 | Candeias 2008; Kanjilal 1995 |
|
| Melanoma | PTB | SNP | SNP at position 119 in the 5′ UTR of | Khan 2013 |
|
| Diffuse large B-cell lymphoma (DLBCL) | miR125-b | SNV | Three SNVs disrupt the interaction between miR-125b and the | Li 2013 |
Figure 3.MDM2’s switch from a negative to a positive regulator of p53 following DNA damage is dependent on the p53 mRNA. (A) Under normal conditions, MDM2 (in red) binds and catalyzes the ubiquitination of p53, targeting it for degradation via the 26S proteasomal pathway (of note, p53 degradation can also take place in the nucleus (165)). (B) Following DNA damage, ATM phosphorylates MDM2 at Ser395 (in green) that allows MDM2 to interact with the p53 mRNA. This promotes the interaction with the 5S RNP complex and an increase in p53 synthesis. The p53 mRNA–MDM2 is required to bring ATM to the p53 polysome where it phosphorylates the nascent p53 protein to prevent MDM2-mediated degradation of the newly synthesized p53. A single synonymous mutation in the p53 mRNA at codon 22 prevents MDM2 from binding the p53 mRNA and prevents the stabilization of p53 following genotoxic stress.